NCT00985387View on ClinicalTrials.gov

Evaluation of Adherence to Solifenacin Treatment in Overactive Bladder Patients

CompletedOBSERVATIONAL
Enrollment

1,215

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Urinary Bladder, OveractiveOveractive Bladder
Interventions
DRUG

Solifenacin

oral

Trial Locations (41)

420-717

Bucheon-si

420-767

Bucheon-si

602-702

Busan

602-715

Busan

602-739

Busan

614-735

Busan

200-704

Chuncheon

700-712

Daegu

700-721

Daegu

705-717

Daegu

705-718

Daegu

301-721

Daejeon

302-718

Daejeon

302-799

Daejeon

201-711

Gangneung

730-728

Gumi

501-717

Gwangju

501-757

Gwangju

503-715

Gwangju

780-350

Gyongju

519-809

Hwasun

570-160

Iksan

400-711

Inchon

405-760

Inchon

361-711

Jeonju

380-704

Jeonju

561-712

Jeonju

630-522

Masan

463-707

Seongnam

100-380

Seoul

110-744

Seoul

130-702

Seoul

133-792

Seoul

136-705

Seoul

137-701

Seoul

138-736

Seoul

139-711

Seoul

143-729

Seoul

158-710

Seoul

443-721

Suwon

682-714

Ulsan

Sponsors
All Listed Sponsors
collaborator

Astellas Pharma Korea, Inc.

INDUSTRY

lead

Astellas Pharma Inc

INDUSTRY

NCT00985387 - Evaluation of Adherence to Solifenacin Treatment in Overactive Bladder Patients | Biotech Hunter | Biotech Hunter